Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 9 mechanisms across 64 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

34 trials 10 active 7 sponsors

BCL-2 Inhibitor

10 trials 5 active 3 sponsors

CD20-directed Cytolytic Antibody

9 trials 1 active 7 sponsors

Thalidomide Analog

3 trials 1 sponsor

PI3K-delta/PI3K-gamma

3 trials 2 sponsors

Alkylating Drug

2 trials 2 sponsors

CD52-directed Cytolytic Antibody

1 trials 1 sponsor

Hematopoietic Stem Cell Mobilizer

1 trials 1 sponsor

ABL kinase/BCR-ABL/EPHA2/FYN/LCK/PDGFRβ/SRC/YES/c-KIT

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

287 industry-sponsored trials across 113 sponsors

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2030-05	NCT07218341
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2030-05	NCT06876662
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2030-05	NCT06876649
AstraZeneca	Acalabrutinib capsule	—	COMPLETED	2023-05-02	NCT04930536

Showing 57 of 57 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	RECRUITING	2026-12-31	NCT01804686
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2028-03	NCT06428019
BeOne Medicines	BGB-16673	—	RECRUITING	2028-04-17	NCT06973187
BeOne Medicines	BGB-16673	—	RECRUITING	2028-05-15	NCT06846671
Dizal (Jiangsu) Pharmaceutical Co., Ltd.	DZD8586	—	RECRUITING	2029-01	NCT07139873
BeOne Medicines	Sonrotoclax	—	RECRUITING	2029-09-30	NCT06943872
Newave Pharmaceutical Inc	Rocbrutinib	—	RECRUITING	2029-10-30	NCT07342478
BeOne Medicines	BGB-16673	—	RECRUITING	2029-11-30	NCT06970743
BeOne Medicines	Sonrotoclax	—	RECRUITING	2031-02	NCT07277231
Merck	Nemtabrutinib	—	RECRUITING	2032-06-01	NCT05947851
Merck	Nemtabrutinib	—	RECRUITING	2032-09-07	NCT06136559
Grifols Therapeutics LLC	Xembify	—	RECRUITING	2026-05	NCT05645107
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2025-06-10	NCT05254743
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-10	NCT04965493
Acerta Pharma BV	Acalabrutinib	—	ACTIVE NOT RECRUITING	2027-01-31	NCT03836261
Merck	Nemtabrutinib	—	ACTIVE NOT RECRUITING	2027-05-19	NCT05624554
AstraZeneca	Acalabrutinib	—	ACTIVE NOT RECRUITING	2027-07-15	NCT05057494
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-08	NCT03844048
BeOne Medicines	Sonrotoclax	—	ACTIVE NOT RECRUITING	2032-02	NCT06073821
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2025-07-11	NCT05023980
AstraZeneca	Acalabrutinib	—	ACTIVE NOT RECRUITING	2024-01-03	NCT04075292
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2023-08-29	NCT04666038
Acerta Pharma BV	Acalabrutinib (ACP-196)	—	ACTIVE NOT RECRUITING	2021-09-03	NCT02970318
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-05-07	NCT03336333
Acerta Pharma BV	Acalabrutinib	—	ACTIVE NOT RECRUITING	2020-09-15	NCT02477696
Acerta Pharma BV	Acalabrutinib	—	ACTIVE NOT RECRUITING	2019-02-08	NCT02475681
Nurix Therapeutics, Inc.	NX-5948	—	NOT YET RECRUITING	2029-10	NCT07516093
AstraZeneca	Acalabrutinib	—	COMPLETED	2025-11-04	NCT04008706
Octapharma	Panzyga	—	COMPLETED	2025-09-19	NCT04502030
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-03-19	NCT04285567
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2023-08-18	NCT01724346
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2022-08-08	NCT03734016
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2021-12-29	NCT02980731
AbbVie	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2021-10-12	NCT03406156
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2020-10-27	NCT00774345
SecuraBio	IPI-145	—	COMPLETED	2020-06-12	NCT02049515
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2020-04-01	NCT02301156
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2019-06-10	NCT01569295
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2019-04-10	NCT02756611
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2019-01-23	NCT01611090
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2018-03-26	NCT02264574
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	COMPLETED	2017-05-19	NCT02004522
Roche	Bendamustine	—	COMPLETED	2017-05-08	NCT02005471
Roche	Bendamustine	—	COMPLETED	2016-12-29	NCT01905943
Johnson & Johnson	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2015-12-01	NCT01973387
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2015-05	NCT01722487
Merck	Dinaciclib	—	COMPLETED	2014-12	NCT01580228
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2014-03-31	NCT00910910
Pharmacyclics LLC.	ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-11	NCT01578707
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2013-10	NCT01539512
Lundbeck Canada Inc.	Bendamustine at a dose of 100 mg/m2	—	COMPLETED	2013-06	NCT01500083
TG Therapeutics, Inc.	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2023-02-22	NCT02612311
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-12-20	NCT03801525
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2018-08-15	NCT01659021
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2018-05-21	NCT01539291
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2016-05-30	NCT01980888
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2016-05-13	NCT01980875

Showing 100 of 114 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Ossium Health, Inc.	—	—	RECRUITING	2026-05-31	NCT05589896
Vector Vitale LLC	Zinc-64 Aspartate	—	RECRUITING	2026-07-31	NCT06506643
BeOne Medicines	BGB-16673	—	RECRUITING	2026-11	NCT05006716
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2026-11	NCT04895436
Ascentage Pharma Group Inc.	APG2575	—	RECRUITING	2026-12	NCT05147467
Vironexis Biotherapeutics Inc.	—	—	RECRUITING	2027-06	NCT06533579
Dizal Pharmaceuticals	DZD8586	—	RECRUITING	2027-09	NCT06539182
Curis, Inc.	Emavusertib	—	RECRUITING	2027-11	NCT07271667
Nurix Therapeutics, Inc.	NX-5948	—	RECRUITING	2028-01	NCT07221500
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2028-06	NCT06588478
BeiGene	BGB-16673	—	RECRUITING	2029-01-31	NCT05294731
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2029-05	NCT02966756
Dizal (Jiangsu) Pharmaceutical Co., Ltd.	DZD8586	—	RECRUITING	2029-12	NCT07154264
CRISPR Therapeutics AG	CTX112	—	RECRUITING	2030-01	NCT05643742
IDP Discovery Pharma S.L.	IDP-121	—	RECRUITING	2025-12-22	NCT05908409
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB3909 tablet	—	RECRUITING	2025-12	NCT05959694
Ascentage Pharma Group Inc.	APG-2575	—	RECRUITING	2024-10-20	NCT04494503
Cellectar Biosciences, Inc.	Iopofosine I 131 single dose	—	ACTIVE NOT RECRUITING	2026-06-22	NCT02952508
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	Nemtabrutinib	—	ACTIVE NOT RECRUITING	2026-09-18	NCT03162536
Roche	Venetoclax	BCL-2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-10-31	NCT06524375
BeOne Medicines	Sonrotoclax	—	ACTIVE NOT RECRUITING	2026-11	NCT06637501
BeiGene	Sonrotoclax	—	ACTIVE NOT RECRUITING	2027-06	NCT06697184
Novartis	Rapcabtagene autoleucel single agent	—	ACTIVE NOT RECRUITING	2027-06-30	NCT03960840
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2027-12	NCT04623541
Allogene Therapeutics	ALLO-647	—	ACTIVE NOT RECRUITING	2029-02	NCT04416984
Merck	Zilovertamab vedotin	—	ACTIVE NOT RECRUITING	2029-05-17	NCT05458297
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-035	—	ACTIVE NOT RECRUITING	2025-12	NCT05944978
BeiGene	BGB-11417	—	ACTIVE NOT RECRUITING	2025-01-24	NCT05479994
AstraZeneca	Acalabrutinib	—	ACTIVE NOT RECRUITING	2022-12-22	NCT03932331
Acerta Pharma BV	Acalabrutinib	—	ACTIVE NOT RECRUITING	2021-07-15	NCT02029443
Acerta Pharma BV	ACP-196 (acalabrutinib)	—	ACTIVE NOT RECRUITING	2020-10-16	NCT02717611
MingSight Pharmaceuticals, Inc	MS-553, DS1	—	NOT YET RECRUITING	2028-09	NCT06979076
AstraZeneca	Acalabrutinib	—	NOT YET RECRUITING	2029-05-01	NCT07024706
Nurix Therapeutics, Inc.	NX-5948	—	NOT YET RECRUITING	2033-05	NCT07520006
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2026-01-09	NCT04116437
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2025-10-09	NCT05105841
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	COMPLETED	2025-01-27	NCT03740529
Cyteir Therapeutics, Inc.	CYT-0851	—	COMPLETED	2024-11-30	NCT03997968
Oncternal Therapeutics, Inc	Cirmtuzumab (2-16 kg/mg) plus Ibrutinib	—	COMPLETED	2024-09-25	NCT03088878
BeiGene	BGB-10188	—	COMPLETED	2024-08-28	NCT04282018
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2021-12-22	NCT02141282
Precision BioSciences, Inc.	Fludarabine	—	COMPLETED	2021-06-24	NCT04030195
AbbVie	azacitadine	—	COMPLETED	2021-03-12	NCT02265731
AstraZeneca	Cerdulatinib	—	COMPLETED	2020-12-15	NCT01994382
Pharmacyclics LLC.	ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-11-12	NCT02910583
AbbVie	ABT-199 (Main Cohort)	—	COMPLETED	2020-10-28	NCT01889186
Acerta Pharma BV	Acalabrutinib	—	COMPLETED	2020-07-14	NCT02362035
Acerta Pharma BV	Acalabrutinib (Arm A)	—	COMPLETED	2020-06-26	NCT02337829
Gilead	Tirabrutinib	—	COMPLETED	2019-06-17	NCT02968563
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2019-04-26	NCT01109069
Gilead	Tirabrutinib	—	COMPLETED	2019-02-20	NCT02983617
Roche	bendamustine	—	COMPLETED	2018-11-19	NCT02071225
MorphoSys AG	Tafasitamab	—	COMPLETED	2018-11	NCT02639910
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2018-06-15	NCT03206918
Bristol-Myers Squibb	lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2017-09-05	NCT00963105
Roche	Bendamustine	—	COMPLETED	2016-11-07	NCT02320487
Novartis	HSC835	—	COMPLETED	2016-10-03	NCT01474681
Novartis	HSC835	—	COMPLETED	2016-08-29	NCT01930162
MedImmune LLC	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2016-01-08	NCT01466153
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2015-12	NCT02013128
Polyphor Ltd.	POL6326	—	COMPLETED	2015-11	NCT01413568
SymBio Pharmaceuticals	SyB L-0501	—	COMPLETED	2015-06	NCT02042911
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2015-05	NCT01647971
Aptevo Therapeutics	TRU-016 and bendamustine	—	COMPLETED	2014-12	NCT01188681
TME Pharma AG	NOX-A12	—	COMPLETED	2014-11	NCT01486797
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2014-06	NCT01744691
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2014-01	NCT01868893
AbbVie (prior sponsor, Abbott)	Navitoclax	—	COMPLETED	2013-07	NCT01557777
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2013-06	NCT01217749
Jiangsu Simcere Pharmaceutical Co., Ltd.	Bendamustine hydrochloride injection	—	COMPLETED	2013-06	NCT01109264
MedImmune LLC	CAT-8015 20 mcg/kg	—	COMPLETED	2013-03-04	NCT01030536
Gilead	veltuzumab	—	COMPLETED	2013-03	NCT00546793
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-02	NCT01520922
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2012-12	NCT01105247
Roche	ABT-263	—	COMPLETED	2012-06	NCT01087151
CytRx	bafetinib	—	COMPLETED	2011-12	NCT01144260
BioCryst Pharmaceuticals	forodesine HCl	—	COMPLETED	2010-11	NCT00640523
Zhejiang DTRM Biopharma	DTRM-555	—	TERMINATED	2024-12-31	NCT04305444
Incyte Corporation	tafasitamab	—	TERMINATED	2024-10-22	NCT04809467
MingSight Pharmaceuticals, Inc	MS-553	—	TERMINATED	2023-11-28	NCT03492125
MingSight Pharmaceuticals, Inc	MS-553	—	TERMINATED	2023-11-28	NCT05720052
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQ-B3525 tablets	—	TERMINATED	2023-11-22	NCT04808570
Genmab	GEN3009	—	TERMINATED	2022-11-21	NCT04358458
Hangzhou Zenshine Pharmaceuticals Co., Ltd.	ZX-101A	—	TERMINATED	2022-07-08	NCT04504708
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-05-26	NCT02656303
TG Therapeutics, Inc.	Venetoclax	BCL-2 Inhibitor [EPC]	TERMINATED	2022-05-26	NCT03379051
TG Therapeutics, Inc.	TGR-1202	—	TERMINATED	2022-05-25	NCT03207256
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-05-22	NCT04016805
Aprea Therapeutics	APR-246 (eprenetapopt) + Acalabrutinib in CLL	—	TERMINATED	2021-08-23	NCT04419389
TG Therapeutics, Inc.	Umbralisib	—	TERMINATED	2021-06-10	NCT02742090
Sunesis Pharmaceuticals	SNS-062	—	TERMINATED	2020-08-31	NCT03037645
Sumitomo Pharma America, Inc.	TP-0903	—	TERMINATED	2020-01-21	NCT03572634
Innate Pharma	monalizumab	—	TERMINATED	2018-10-29	NCT02557516
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2018-06-18	NCT01090414
Asana BioSciences	ASN002 Dose Escalation	—	TERMINATED	2018-06	NCT02440685
Gilead	Entospletinib MM	—	TERMINATED	2017-09-14	NCT01799889
Gilead	hLL1-DOX (IMMU-115)	—	TERMINATED	2016-11	NCT01585688
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2016-04-27	NCT02044822
Celldex Therapeutics	CDX-301	—	TERMINATED	2016-03	NCT02200380
Ångstrom Pharmaceuticals	A6	—	TERMINATED	2015-11	NCT02046928

Showing 100 of 112 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Newave Pharmaceutical Inc	LP-118	—	RECRUITING	2026-12-31	NCT04771572
Nurix Therapeutics, Inc.	NX-5948	—	RECRUITING	2027-01	NCT05131022
AbbVie	ABBV-319	—	RECRUITING	2027-02	NCT05512390
Imugene Limited	Azer-cel	—	RECRUITING	2027-06	NCT03666000
Carna Biosciences, Inc.	Docirbrutinib	—	RECRUITING	2027-09	NCT05602363
Schrödinger, Inc.	SGR-1505	—	RECRUITING	2027-11	NCT05544019
Roche	Mosunetuzumab	—	RECRUITING	2028-05-31	NCT05091424
Ono Pharmaceutical Co., Ltd.	ONO-4685	—	RECRUITING	2029-01-31	NCT06547528
Umoja Biopharma	rapamycin	—	RECRUITING	2029-03	NCT06528301
Nurix Therapeutics, Inc.	NX-2127	—	RECRUITING	2026-05	NCT04830137
Lomond Therapeutics Holdings, Inc.	ZE 50-0134	—	RECRUITING	2026-03	NCT06708897
CytoCares Inc	CC312	—	RECRUITING	2026-03	NCT06037018
Miltenyi Biomedicine GmbH	MB-CART19.1	—	ACTIVE NOT RECRUITING	2026-06	NCT03853616
AbbVie	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2027-07	NCT06291220
AbbVie	ABBV-525	—	ACTIVE NOT RECRUITING	2029-07	NCT05618028
BeOne Medicines	BGB-21447	—	ACTIVE NOT RECRUITING	2026-05	NCT05828589
Sana Biotechnology	SC291	—	ACTIVE NOT RECRUITING	2025-11-04	NCT05878184
Fate Therapeutics	FT819	—	ACTIVE NOT RECRUITING	2025-06-18	NCT04629729
Bio-Path Holdings, Inc.	L-Bcl-2 antisense oligonucleotide	—	ACTIVE NOT RECRUITING	2025-04	NCT04072458
Nkarta, Inc.	NKX019	—	ACTIVE NOT RECRUITING	2025-03-31	NCT05020678
Ascentage Pharma Group Inc.	APG-2575	—	ACTIVE NOT RECRUITING	2024-10-20	NCT03913949
Fochon Pharmaceuticals, Ltd.	FCN-338	—	ACTIVE NOT RECRUITING	2024-04-28	NCT04682808
Acerta Pharma BV	Ceralasertib	—	ACTIVE NOT RECRUITING	2021-09-07	NCT03328273
Acerta Pharma BV	acalabrutinib	—	ACTIVE NOT RECRUITING	2020-07-20	NCT02157324
Ascentage Pharma Group Inc.	APG-3288	—	NOT YET RECRUITING	2029-12	NCT07424833
Regeneron	Odronextamab multiple dose levels	—	COMPLETED	2025-08-21	NCT02290951
Prelude Therapeutics	PRT2527	—	COMPLETED	2025-06-12	NCT05665530
Johnson & Johnson	JNJ-64264681	—	COMPLETED	2025-01-16	NCT04657224
Iovance Biotherapeutics, Inc.	IOV-2001	—	COMPLETED	2024-11-11	NCT04155710
Xencor, Inc.	XmAb13676	—	COMPLETED	2024-04	NCT02924402
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Zilovertamab vedotin	—	COMPLETED	2023-12-18	NCT03833180
Boryung Pharmaceutical Co., Ltd	BR101801 (Phase Ia)	—	COMPLETED	2023-09-21	NCT04018248
Cyclacel Pharmaceuticals, Inc.	CYC065	—	COMPLETED	2022-11-15	NCT03739554
AbbVie	ABT-199	—	COMPLETED	2022-06-23	NCT01682616
TG Therapeutics, Inc.	Umbralisib	—	COMPLETED	2021-11-04	NCT02535286
AstraZeneca	AZD4573	—	COMPLETED	2021-09-30	NCT03263637
Acerta Pharma BV	acalabrutinib	—	COMPLETED	2021-08-20	NCT02296918
Bristol-Myers Squibb	CC-115	—	COMPLETED	2021-03-12	NCT01353625
Zhejiang DTRM Biopharma	DTRMWXHS-12	—	COMPLETED	2020-11-23	NCT02900716
miRagen Therapeutics, Inc.	Cobomarsen	—	COMPLETED	2020-10-06	NCT02580552
AbbVie	ABT-199	—	COMPLETED	2020-05-08	NCT01328626
TG Therapeutics, Inc.	Ublituximab + TGR-1202	—	COMPLETED	2019-10	NCT02006485
ADC Therapeutics S.A.	ADCT-402	—	COMPLETED	2019-02-21	NCT02669017
Zhejiang DTRM Biopharma	DTRMWXHS-12	—	COMPLETED	2019-02	NCT02891590
Roche	Bendamustine	—	COMPLETED	2018-08-17	NCT01671904
TG Therapeutics, Inc.	TGR-1202	—	COMPLETED	2018-02	NCT01767766
TG Therapeutics, Inc.	TGR-1202 + Obinutuzumab + Chlorambucil	—	COMPLETED	2017-11	NCT02100852
Merck KGaA, Darmstadt, Germany	MSC2490484A (M3814)	—	COMPLETED	2017-06-29	NCT02316197
Millennium Pharmaceuticals, Inc.	Alisertib	—	COMPLETED	2016-10-01	NCT00697346
ImmunoGen, Inc.	IMGN529	—	COMPLETED	2016-07	NCT01534715
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2016-06-24	NCT02381080
Celldex Therapeutics	CDX-1127	—	COMPLETED	2015-12	NCT01460134
Tragara Pharmaceuticals, Inc.	TG02 citrate	—	COMPLETED	2015-07	NCT01699152
Bristol-Myers Squibb	AVL-292	—	COMPLETED	2015-06-26	NCT01351935
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2015-04-28	NCT01088048
Roche	DCDT2980S	—	COMPLETED	2015-03	NCT01209130
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2014-12-25	NCT02242045
Traws Pharma, Inc.	ON 01910.Na	—	COMPLETED	2014-11	NCT00854646
Bristol-Myers Squibb	BMS-936564 (Anti-CXCR4)	—	COMPLETED	2014-11	NCT01120457
Sanofi	SAR245409	—	COMPLETED	2014-05	NCT01410513
Pfizer	BMN 673	—	COMPLETED	2014-03-31	NCT01399840
Amgen	AMG 319	—	COMPLETED	2013-10	NCT01300026
Fate Therapeutics	Single FT1050 treated UCB unit	—	COMPLETED	2013-10	NCT01527838
Merck	Dinaciclib	—	COMPLETED	2013-10	NCT01650727
Threshold Pharmaceuticals	TH-302	—	COMPLETED	2013-08	NCT01149915
Gilead	Treatment A	—	COMPLETED	2013-08	NCT01841489
AbbVie (prior sponsor, Abbott)	ABT-348	—	COMPLETED	2013-06	NCT01110473
AbbVie (prior sponsor, Abbott)	ABT-263	—	COMPLETED	2013-05	NCT00868413
Xencor, Inc.	XmAb5574	—	COMPLETED	2013-01	NCT01161511
American Regent, Inc.	Luitpold Azacitidine	—	COMPLETED	2012-12	NCT01290302
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2012-11	NCT01292135
Millennium Pharmaceuticals, Inc.	TAK-901	—	COMPLETED	2012-09	NCT00807677
Roche	Polatuzumab Vedotin	—	COMPLETED	2012-06-29	NCT01290549
Aptevo Therapeutics	TRU-016 (anti-CD37 protein therapeutic)	—	COMPLETED	2011-12	NCT00614042
Gilead	CAL-101	—	COMPLETED	2011-12	NCT00710528
Tesaro, Inc.	MK-4827	—	COMPLETED	2011-09	NCT00749502
Laboratoire français de Fractionnement et de Biotechnologies	LFB-R603	—	COMPLETED	2011-08	NCT01098188
AbbVie	navitoclax	—	COMPLETED	2011-05	NCT01121133
Memgen, LLC	ISF35	—	COMPLETED	2011-04	NCT00772486
Genzyme, a Sanofi Company	plerixafor	Hematopoietic Stem Cell Mobilizer [EPC]	COMPLETED	2010-11	NCT00694590
Abbott	ABT-263	—	COMPLETED	2010-10	NCT01021358
Abbott	ABT-263	—	COMPLETED	2010-08	NCT00743028
Bristol-Myers Squibb	MDX-1342	—	COMPLETED	2010-05	NCT00593944
Biomea Fusion Inc.	BMF-219	—	TERMINATED	2025-02-13	NCT05153330
IGM Biosciences, Inc.	Aplitabart (IGM-8444)	—	TERMINATED	2025-01-20	NCT04553692
Novartis	JBH492	—	TERMINATED	2024-09-05	NCT04240704
MEI Pharma, Inc.	voruciclib monotherapy	—	TERMINATED	2024-07-24	NCT03547115
TG Therapeutics, Inc.	TG-1801	—	TERMINATED	2024-06-12	NCT04806035
TG Therapeutics, Inc.	TG-1701	—	TERMINATED	2024-05-21	NCT03671590
Aptose Biosciences Inc.	CG-806	—	TERMINATED	2024-05-17	NCT03893682
Prelude Therapeutics	PRT1419	—	TERMINATED	2024-01-19	NCT05107856
Novartis	VAY736	—	TERMINATED	2023-09-29	NCT03400176
Fate Therapeutics	FT596	—	TERMINATED	2023-09-27	NCT04245722
Lava Therapeutics	LAVA-051	—	TERMINATED	2023-09-06	NCT04887259
Vincerx Pharma, Inc.	VIP152	—	TERMINATED	2023-05-26	NCT04978779
MEI Pharma, Inc.	ME-401	—	TERMINATED	2023-03-29	NCT02914938
Exelixis	XL114	—	TERMINATED	2022-11-01	NCT05144347
Kite, A Gilead Company	brexucabtagene autoleucel	—	TERMINATED	2021-02-12	NCT03624036
Tarix Pharmaceuticals	TXA127 300 mcg/kg/day	—	TERMINATED	2020-12	NCT01300611
Aptevo Therapeutics	20 mg/kg TRU-016 + Rituximab	—	TERMINATED	2020-02-24	NCT01644253

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Chronic Lymphocytic Leukemia

BTK (5)

Novel Drugs by Company (New molecular entities)

Roche 2 drugs

WAYLIS THERAP 1 drug

SECURA 1 drug

AstraZeneca 1 drug

ACALABRUTINIB MALEATE

LOXO ONCOL 1 drug

Amgen 1 drug

Reformulations (9 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.